Morgan Stanley Expects Gilead Sciences (GILD) to Prosper as Biopharma Policy Uncertainties Dissipate in 2026
Gilead Sciences Inc. (NASDAQ:BROWN) is one of the best stocks for the next decade. On Dec. 12, Morgan Stanley raised the company’s price target for Gilead to $151 from $147 with an Overweight rating on the stock. The company informed investors that the regulatory and political uncertainties currently weighing on the biopharmaceutical are expected to…